Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia

NCT03258931 is registered in ClinicalTrials.gov with Arog Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03258931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03258931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia
Lead sponsor
Arog Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 15, 2018
Completion date
April 6, 2026
Enrollment
214 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed flt3 mutated aml